To Study the Impact of CPAP on Gait Parameters in OSA Patients

Overview

To study the impact of CPAP therapy on gait in patients with obstructive sleep apnea syndrome.

Full Title of Study: “Impact of the CPAP on Gait in OSA Patients”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: August 2009

Detailed Description

To study the impact of CPAP therapy on gait velocity and temproral gait in patients with obstructive sleep apnea syndrome using the SMTEC system. Patients will be assessed before and 8 weeks after CPAP therapy.

Interventions

  • Device: CPAP therapy
    • 8 weeks of CPAP therapy

Arms, Groups and Cohorts

  • On CPAP therapy
    • OSA patients assessed before and after 8 weeks of CPAP therapy

Clinical Trial Outcome Measures

Primary Measures

  • Gait parameters: gait velocity [m/s]
    • Time Frame: 8 weeks

Participating in This Clinical Trial

Inclusion Criteria

  • OSA patients newly diagnosed Exclusion Criteria:

  • acute medical illness in the past months – neurological and psychiatric diseases – orthopaedic, rheumatologic or any sensory conditions affecting normal walking

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Geneva
  • Provider of Information About this Clinical Study
    • Principal Investigator: Gilles Allali, Dr – University Hospital, Geneva
  • Overall Official(s)
    • Gilles Allali, MD/PhD, Principal Investigator, University Hospital, Geneva

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.